This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Eosinophilic Driven Diseases Management Forum

Wednesday, March 30, 21:00

30 Mar, 2022

Webcast

Register Now

Eosinophilic Driven Diseases Management Forum

Nucala is now approved in 4 indications in Saudi Arabia and the objective of the meeting is to raise Saudi HCPs awareness about the management of Eosinophilic Driven Diseases
1

Speakers

 Speaker

Dr. Hussain Juwaid

Head of Severe Asthma and Airway Diseases Unit, Consultant of Chest and Sleep Medicine at Prince Sultan Medical Military City.

 Speaker

Dr. Hajar Al-Hayyan

Pulmonary Consultant King Saud bin Abdulaziz University National Guard Hospital, Riyadh

 Speaker

Dr. Tariq Tatwani MD, FRCS

Rhinologist Skull base Surgeon, Prince Sultan Military Medical City

 Speaker

Prof. Emilio Pizzichini

Global Medical Expert, GSK Works at University Hospital of UFSC (Federal University of Santa Catarina), Florianopolis, Santa Catarina –Brazil. Professor of Respiratory Medicine and Head of the Asthma and Airway Inflammation Centre (NUPAIVA) at the Universidad Federal de Santa Catarina in Florianópolis, Brazil.


Agenda

21:00 - 21:10 - Welcoming & introduction

21:10 - 21:30 - Severe Asthma Diagnoses, Comorbidities and Management.

21:30 - 21:50: Chronic Rhinosinusitis and the Role of Biologics.

21:50 - 22:10 - Mepolizumab Overview in Severe Asthma Management and CRSwNP.

22:10 - 22:30 - Q & A.

Trademarks are owned by or licensed to the GSK group of companies.

This Event is organized by GSK in collaboration with the Saudi Society of Internal Medicine and intended for healthcare professionals in Saudi Arabia only.

Reference:

  1. Nucala Summary of Product Characteristics, July 2021.

PM-SA-MPL-WCNT-220001

Date of preparation February 2022